Rather, RCND should be regarded as a heterogeneous syndrome involving multiple interacting mechanisms, including genetic abnormalities (e.g., mutations in FLCN or BRCA2), TGF-β1-mediated fibrotic signaling, immune-driven inflammation, fibrotic remodeling of the tumor microenvironment, and breed-specific genetic predispositions. The gene discussed is BRCA2; the disease is neoplasm.